Activation of AMPK by phosphorylation reduces de novo lipogenesis and augments fatty acid oxidation in NAFLD by downstream factors covering SREBP-1c, ACC1 and FAS [22, 33]. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.